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Abstract 
Obstructive Sleep Apnea (OSA) is the most common respiratory disorder in Western societies: according to a 
first recent worldwide epidemiological study, it was estimated that 936 million patients aged 30-69 years with 
mild to moderate OSA and 425 million patients aged 30-69 years with severe OSA requiring CPAP treatment. 
Recently, the Centre for Research on Health and Social Care Management (CERGAS) at the Bocconi University 
of Milan has estimated that in Italy, the prevalence of moderate to severe OSA occurs in the 27% of the general 
population, with an overall prevalence of mild to medium-severe OSA of more than 24 million people aged be-
tween 15 and 74 years (54% of the adult population), while from a practical point of view, Italian doctors diag-
nosed only 460.000 moderate-severe patients (4 per cent of the estimated prevalence) and 230,000 patients were 
treated (2 per cent of the estimated prevalence), highlighting a substantial gap between diagnosis and treatment.  
In addition, OSA patients are often obese and the close correlation between the two conditions suggests that the 
prevalence of OSA will increase in the short term as obesity increases. At the individual level, OSA leads to a 
significant decrease in quality of life (HRQoL) and intellectual and mechanical/functional capacities with reduced 
physical activity, as well as a marked increase in sudden death and risk of cardiovascular and metabolic diseases. 
Emerging epidemiological data also suggest that the severity of OSA associated with the severity of chronic noc-
turnal hypoxemia (CIH) correlates with an increased risk of diabetes mellitus, metabolic syndrome (MS) and can-
cer. OSA is also an important risk factor for high blood pressure, acute and chronic atrial fibrillation (FAC), 
chronic coronary artery disease (CAD) and stroke. 
It is therefore intuitive that at the social level, OSA also leads to a decline in economic productivity. 
This article addresses OSA from a new epidemiological perspective, according to the latest prevalence studies, 
and addresses emerging problems related to the diagnosis. 
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1. Introduction 
 
Obstructive Sleep Apnea (OSA) is defined as a 
very common disorder in the general popula-
tion characterized by loud and habitual noctur-
nal snoring with repetitive upper airway ob-
struction (apnea) (Paul E Peppard et al. 2013; 
Heinzer et al. 2015) sometimes accompanied by 
daytime sleepiness. The severity of OSA is gen-
erally measured by the Apnea-Hypopnea Index 
(AHI) which defines the number of nocturnal 
respiratory pauses (apnea) or partial and/or in-
complete pauses (hypopnea) and/or obstructive 
events measured per hour of sleep. 
The diagnostic definition of OSA is obtained 
from both polysomnography recording (PSG) 
from which the AHI index, which must be ≥5 
events/hour of sleep, and from the night-time 
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cardio-respiratory monitoring (MCRN). In the 
best-known American epidemiological study, 
called the Wisconsin Sleep Cohort Study, the 
prevalence of OSA in the general American 
population was estimated to be around 24 per-
cent in men and 9 percent in women between 
30 and 60 years of age (Punjabi 2008) 
Current prevalence predictions indicate a 
worldwide increment and suggest that OSA is 
present in both developing countries and West-
ern societies (Kapur 2010) 
New data from a first worldwide epidemiologi-
cal study published in August 2019 on Lancet 
carried out in 16 countries, and from the analy-
sis of the results of 17 new epidemiological 
prevalence studies, all carried out with the new 
instrumental diagnostic criteria of the American 
Academy Sleep Medicine (AASM) of 2012 (new 
diagnostic definition of hypopnea and arousal) 
suggest that the prevalence of the disease 
worldwide can be estimated at around 936 mil-
lion patients with mild to moderate OSA, (al-
most one billion!) aged 30-69 years and 425 mil-
lion patients with severe OSA aged 30-69 years 
who need night-time CPAP treatment 
(Benjafield et al. 2019) 
 
2. OSA and obesity: a close relationship 
 
Obesity is an epidemic disease with a rapid pro-
gression in Western society (Armeni et al. 
2019). Obesity, defined as body mass index 
(BMI) >30, is the most important risk factor 
for the onset of OSA, in particular when the fat 
distribution is prevalent in the thoracic-
abdominal area. In the multi-center Wisconsin 
Sleep Study, it is reported that in OSA patients 
body weight gain over a 4-year period is an im-
portant predictor of OSA progression; the 
study showed that in OSA patients, a 10 per-
cent increase in body weight resulted in a 32 
percent increase in the AHI metric index, with 
a relative 6-fold increase in the risk of develop-
ing an even more severe form of OSA (Paul E. 
Peppard et al. 2000) Another multicentre epi-
demiological study, Sleep Heart Health Study, 
conducted on native Americans over 65 years 
of age, also showed that a 10 kg weight gain 
over a 5-year observation period resulted in a 
2.5-fold increase in AHI with a 5.2 percent in-
crease in the risk of developing OSA-related 
cardiovascular disease (Newman et al. 2005) 
In addition, according to another epidemiologi-
cal study carried out in bariatric surgery, OSA is 
present in 41 percent of patients with BMI >28 
and 78 percent of severe obese patients with 
BMI >35 who have to undergo bariatric sur-
gery (Domenico Maurizio Toraldo et al. 2013; 
Lopez et al. 2008). In obese patients with severe 
OSA, obesity is considered responsible for 
sleep deprivation and changes in sleep architec-
ture, which leads to comorbid insomnia, which 
worsens the quality of sleep and life of obese 
OSA patients (Spiegel et al. 2005). The altera-
tions of the diet and of the alimentary style in 
paediatric age, can determine alterations of the 
neuro-hormonal regulation of leptin and greline 
that can favour, with the years, the develop-
ment of OSA. A series of clinical studies have 
demonstrated in the obese OSA patient the 
presence of elevated serum levels of functional-
ly altered neuro-hormonal leptin; leptin is a 
hunger inhibitor and intervenes in the regula-
tion of body weight together with greline and 
affects the neurological centers of breathing 
during sleep; treatment with continuous posi-
tive airway pressure (CPAP) determines an im-
provement in serum leptin levels with an im-
provement in obesity and respiratory activity 
during sleep (Chen et al. 2015; Phillips et al. 
2000; Ong et al. 2013). 
Recently, a longitudinal controlled clinical study 
was conducted in Sweden on more than 3,400 
severely obese patients with OSA, using laparo-
scopically adjustable gastric banding to reduce 
body weight in severe OSA. In this study, the 
decrease in BMI resulted in a marked im-
provement in OSA symptoms (quality of life 
and daytime sleepiness) and in a decrease in the 
use of drugs for the treatment of diabetes melli-
tus 2 (DM) and metabolic syndrome (MS). In 
another clinical study of severe obese patients 
(BMI >35) with severe OSA (AHI >30/hs), 
bariatric surgery resulted in significant weight 
loss and a decrease in OSA severity evidenced 
by a reduction in AHI from 80 to 17.7 ±10.0 
obtained after about 5 months of surgery 
(Dixon, Schachter, and O’Brien 2005) Howev-
er, the majority of OSA patients who under-
went bariatric surgery, after surgery, after about 
6 months demonstrated a significant residual 
OSA (AHI >15) at a control PSG, and special 
attention should be paid in the protocol for the 
repetition of PSG in the follow-up of operated 
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patients and for CPAP treatment if the AHI in-
dex should be >10 (Greenburg, Lettieri, and 
Eliasson 2009; Lettieri, Eliasson, and 
Greenburg 2008). Leptin is therefore a hor-
mone involved in appetite suppression, it is re-
leased from adipocytes located in abdominal fat 
and is produced in proportion to the abdominal 
fat content (Münzberg and Morrison 2015); it 
acts on respiratory centers to stimulate ventila-
tion in response to peripheral hypercapnia in 
OSA with the aim of reducing the increased 
PaCO2 and normalizing PaO2. Physiologically 
ineffective leptin increase has been associated 
with worsening of OSA and metabolic syn-
drome (D M Toraldo et al. 2015; Kalra 2008). 
 
3. Genetic factors 
 
The OSA recognizes multiple predisposing fac-
tors of a genetic family type. Given the com-
plexity of the syndrome, it is not possible to 
recognize a single genetic factor that can de-
termine its manifestation, but a set of genetic-
biological factors. The risk of OSA is genetical-
ly predisposed in 40% of cases (Kent, Ryan, 
and McNicholas 2010; Redline and Tishler 
2000). 
The prevalence of OSA in first-degree relatives 
of OSA patients ranges from 22 to 84 percent 
(Mathur and Douglas 1995). Anatomical risk 
factors for OSA, such as obesity and structural 
changes in the soft tissues of the upper first 
airway such as macroglossia and mandibular 
hypoplasia, show familiarity. Obesity and upper 
airway alterations often occur from early child-
hood and studies of monovular twins have 
shown 57-86 percent heritability from early 
youth (Silventoinen and Kaprio 2009) 
Another study in a Scottish population identi-
fied a strong family genetic component for 
OSA and suggested that hereditary craniofacial 
malformations were more important than obe-
sity itself (Mathur and Douglas 1995). Indeed, 
the morphology of the pharyngeal lateral wall, 
the properties of the craniofacial mucosa and 
neck fat have a significant level of heritability 
and therefore susceptibility for OSA. 
 
4. Economic aspects and quality of life 
 
OSA has a significant economic impact on 
Western public health systems and must be 
considered and managed as a chronic condition 
and not, as is the case in Italy, as an acute pa-
thology (the recognition of chronic pathology 
implies the adoption of an ad hoc government 
law). OSA is burdened by direct costs, which 
are the healthcare costs necessary for the diag-
nosis and treatment of the disease and the asso-
ciated comorbidities as well as for the use of 
hospital admissions, and by indirect or social 
costs, very high, due to a reduction in work 
productivity, permanent disability due to road 
or work accidents. This is compounded by the 
overall economic impact of the OAS, which is 
very high. 
In the United States, according to an article by 
the American Academy Sleep Medicine 
(AASM) of 2016 (Nieto et al. 2012) the annual 
cost for an undiagnosed OSA patient is esti-
mated to be around $5,500 (considering direct 
and indirect health care costs), while in diag-
nosed OSA patients it drops to $2,100 per year 
(Campos-Rodriguez et al. 2013b) Patients with 
sleep disorders are less productive than those 
without such disorders and have a higher level 
of absenteeism and decreased productivity at 
work due to fatigue, chronic fatigue and exces-
sive daytime sleepiness (Sherman 2013) Occu-
pational accidents are also more common in pa-
tients with OSA (Alghanim et al. 2008) Several 
studies have shown that the quality of life 
measured with QOLi questionnaires is unfa-
vourable in OSA patients compared to non-
OSA patients and improves after various medi-
cal, ventilatory, dental and surgical therapies 
(Alghanim et al. 2008; Smith and Shneerson 
1995; Jenkinson, Stradling, and Petersen 1997). 
The bedfellow of an untreated OSA patient 
may also suffer from insomnia due to loud 
snoring at night. The QOLi of the untreated 
snoring OSA patient's bed partner significantly 
improves when the OSA is successfully treated 
(Gall, Isaac, and Kryger 1993; Parish and Lyng 
2003). 
 
5. OSA and cardiovascular disease 
 
The strongest scientific evidence supporting an 
independent role for OSA in the promotion of 
early atherosclerosis and the development of 
adverse cardiovascular outcomes (cerebral 
strokes, myocardial infarction and complicated 
vascular aneurysm) can be found in clinical 
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studies addressing the relationship between 
OSA and arterial hypertension (Paul E. 
Peppard et al. 2013) . There are controlled clin-
ical trials that have shown a correlation between 
OSA severity and the likelihood of developing 
hypertension with its complications (Hedner et 
al. 2006; Javier Nieto et al. 2000) 
Recent European data show that out of 11,900 
patients participating in the European study 
called Cohort Apnea Study (ESADA), chronic 
intermittent nocturnal hypoxemia with deep de-
saturations is a predictive factor for early vascu-
lar atherosclerosis and that it can be a key factor 
for the development of arterial hypertension 
and early vascular endothelial damage (vascular 
aneurysm) (Tkacova et al. 2014). The results of 
another clinical study have shown an increased 
propensity in OSA patients for the develop-
ment of hypertension and cardiovascular com-
plications (P E Peppard et al. 2000). In another 
epidemiological study, carried out on 709 sub-
jects, the presence of severe OSA conferred a 
very high risk to diagnose hypertension, regard-
less of other factors such as diet, obesity and 
smoking history. Other recent clinical data from 
a Spanish study also confirmed this same rela-
tionship (José M. Marin et al. 2012; Kent et al. 
2013) 
With regard to chronic ischemic heart disease 
with CAD, recent data suggest that CAD is 
very widespread in patients with OSA and con-
stitutes about 30 percent of patients with CAD, 
and vice versa that patients with CAD are more 
likely to develop an obstructive pathology dur-
ing sleep type OSA (Mooe et al. 1996). In an-
other epidemiological study called Health Study 
carried out on more than 6,000 patients, the se-
verity of CAD (measured as atherosclerotic 
plaque diameter) was correlated to the severity 
of the AHI metric index (SHAHAR et al. 2001) 
In addition, patients with OSA are at high risk 
of developing paroxysmal atrial fibrillation 
(FAP); in another study involving 566 patients 
with chronic ischemic heart disease, severe 
OSA was found and this was associated with a 
fourfold probability of developing FAP (Mehra 
et al. 2006). 
In OSA patients, the increased diameter and 
size of the left cardiac atrial chamber deter-
mines an increased presence of risk factors for 
the appearance of FAP and subsequent failure 
of the subsequent pharmacological cardiover-
sion (Drager et al. 2010). In addition, recur-
rence of FAP becomes less likely if it is signifi-
cantly reduced with the initiation of CPAP 
treatment (Kanagala et al. 2003). Obstructive 
sleep pathology is also an independent predic-
tor of ventricular arrhythmia, particularly in 
subjects with chronic heart failure (Monahan et 
al. 2012). 
OSA is much more common in patients who 
have had a recent stroke or transient ischemic 
attack such as TIA, in 32-63 percent of patients 
compared to the general population, and is as-
sociated with increased mortality and worse 
functional outcomes over time (Bassetti and 
Aldrich 1999; Good et al. 1996). In addition, 
the prevalence of cerebrovascular disease seems 
to increase with increasing severity of OSA. 
Some prospective studies suggest that the pres-
ence and severity of OSA is a predictive factor 
for stroke (Arzt et al. 2005; Yaggi et al. 2005; 
Redline et al. 2010). 
 
6. OSA and cancer 
 
The fundamental pathophysiological mecha-
nism that characterizes OSA is represented by 
chronic nocturnal intermittent hypoxia (CHI) 
that generates a chronic inflammatory cascade 
that causes a diffuse vascular epithelial damage 
of pro-atherogenic type (Garvey, Taylor, and 
McNicholas 2009) the same chronic inflamma-
tory mechanism could promote the develop-
ment of cancer through the release of angiogen-
ic factors. 
In a murine model of OSA, the possibility of 
developing malignant tumors towards blood or 
skin cells (malignant melanoma) by triggering 
mechanisms of systemic inflammation, oxida-
tive stress and immune dysregulation has been 
demonstrated (Isaac Almendros et al. 2013). 
Data from these animal models suggest that 
exposure to CIH in humans may determine the 
origin of malignant cellular neoformation and 
increase distant metastatic progression and 
spread (I Almendros et al. 2012; Nieto et al. 
2012) 
Therefore, several longitudinal clinical studies 
in humans have been proposed that have as-
sessed the association between OSA and can-
cer. In an analysis of 1,522 patients participating 
in the Wisconsin Sleep Cohort Study, subjects 
with severe OSA were at almost five times the 
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risk of developing cancer (Campos-Rodriguez 
et al. 2013a). Similarly, in another Spanish clini-
cal study of nearly 5,000 OSA patients, the se-
verity of the disease expressed by the intensity 
of nocturnal hypoxemia predicted the devel-
opment of malignant neoplasms in different 
body districts (Kendzerska et al. 2014). A Ca-
nadian retrospective cohort study has shown 
that there is a close relationship between OSA 
and cancer, and among other things within this 
population an independent association between 
smoking-related cancer and severity of chronic 
nocturnal hypoxemia has been demonstrated 
(Young et al. 1993). To date, no data have been 
published about the effect of CPAP therapy on 
cancer, and potentially innovative clinical trials 
are being conducted in this area. 
 
7. Diagnosis Considerations 
 
Clinically defined OSA syndrome in combina-
tion with excessive daytime sleepiness (ESD) 
and obesity is estimated to increase in the com-
ing years in both women and men due to in-
creased obesity (Al Lawati, Patel, and Ayas, 
n.d.) OSA, a chronic disease, if left untreated is 
associated with an increase in overall mortality 
and a number of serious social and health con-
sequences such as reduced quality of life, re-
duced productivity in the workplace and in-
creased road and work accidents (De 
Benedetto, Garbarino, and Sanna 2017; Jose M. 
Marin et al. 2005) 
The gold standard diagnostic investigation is 
complete, stationary polysomnography (PSG) 
with neurological and video-surveillance elec-
trodes that is performed in a sleep laboratory 
(LS) and is the preferred method to diagnose 
OSA correctly and completely (D M Toraldo et 
al. 2017). The treatment, not pharmacological, 
is the application of CPAP device (continuous 
positive pressure in the upper airway) which is 
performed in LS with high health care costs 
(manual night titration supported by a neuro-
physiology technician). Due to the high costs 
and long waiting times to perform the examina-
tion, new simplified but equally suitable and 
important methods for home sleep testing 
(HST) have been developed. These are low-
cost, portable and non-permanent instruments, 
defined as polygraphs (night cardiorespiratory 
monitoring, MCRN) which, in addition to mak-
ing the diagnosis, also offer the possibility of 
home treatment by self-titling positive airway 
pressure (APAP). A number of studies com-
pared the complete polysomnography per-
formed in LS with HST, confirming the diag-
nostic non-inferiority of the latter, and also val-
idated home treatment with CPAP device. The 
diagnostic and therapeutic non-inferiority of 
HST vs LS has also been confirmed by other 
studies (D M Toraldo et al. 2017) 
The metric index expressed as AHI/hs is used 
to diagnose the degree of OSA severity by pol-
ygraph/polysomnography recording. A distinc-
tion is made between mild (5-15 events/hour), 
moderate (15-30 events/hour), severe (>30 
events/hour) and very severe (>60 
events/hour). A threshold value of 5 is consid-
ered a sign of normalcy in adult patients. 
In the case of AHI <5 the patient can be con-
sidered negative for the diagnosis of OSA, un-
less the daytime sleepiness symptom is present, 
in which case the patient should undergo LS 
night polysomnography (doubtful cases). The 
test is considered positive for the diagnosis of 
OSA if AHI ≥5 (2,16,17). 
In conclusion, OSA (Passàli et al. 2014; Costa 
and De Benedetto 2017) leads to impairment of 
quality of life, increased risk of cardiovascular 
and metabolic complications and poor work 
performance as well as the possibility of causing 
road and work accidents.
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